Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594
(Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in
colorectal carcinoma patients who are refractory to or intolerant to standard therapy.